NHS pressures put “huge question mark over policy plans” – NAO
This article was originally published in Clinica
The scale of the impact of the NHS’s financial pressures on some hospital trusts has been laid bare by the National Audit Office (NAO), adding weight to fears that service quality and access will suffer.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.